Cat. No.: HY-N0513

Loganic acid

Customer Review

Based on 1 Customer Validation

Loganic acid is an iridoid isolated from cornelian cherry fruits. Loganic acid inhibits NF-κB signaling pathway, activates Nrf2 signaling pathway, exhibits anti-inflammatory activity. Loganic acid can modulate diet-induced atherosclerosis and redox status. Loganic acid has strong free radical scavenging activity and remarkable cyto-protective effect against heavy metal mediated toxicity. Loganic acid is orally active.

For research use only. We do not sell to patients.

Purity: 99.05%
CAS No.: 22255-40-9
Formula: C₁₆H₂₄O₁₀
Molecular Weight:376.36

Storage:

4°C, protect from light

* In solvent : -80°C, 6 months; -20°C, 1 month (protect from light)

Loganic acid Chemical Structure

CAS No.: 22255-40-9

Size

Price

Stock

Quantity

Amount: USD 0.00

* Please select Quantity before adding items.

Top Publications Citing

Use of MCE Products

Fluorescent Dye

Strong Fluorescence Signal / Multi-Disciplinary Applications / High Fluorescence Specificity

Biological Activity
- Description
- Cellular Effect
- In Vitro
- In Vivo
Chemical Information
Solvent & Solubility
- In Vitro
- In Vivo
Purity & Documentation
References
Help & FAQs
Classifications
Bioz

Biological Activity

Description

All NF-κB Isoforms :

Cellular Effect

Cell Line	Type	Value	Description	References
Huh-7	IC₅₀	11 μg/mL Compound: 6, ASB-00012341-005	Antiviral activity against HCV infected in human Huh7 cells assessed as inhibition of viral replication after 72 hrs by NS5A staining Antiviral activity against HCV infected in human Huh7 cells assessed as inhibition of viral replication after 72 hrs by NS5A staining	[PMID: 19904996]

In Vitro

Loganic acid exhibits antioxidant activity, scavenges DPPH free radicals, superoxide anion free radicals, and hydroxyl free radicals with IC₅₀s of 149 μg/mL, 632.43 μg/mL and 29.78 μg/mL, respectively^[2].
Loganic acid (100 μg/mL, 24 h) prevents heavy metal-induced cytotoxicity in PBMC, inhibits HgCl₂-induced ROS generation and lipid peroxidation^[2].
Loganic acid (0-50 µM, 5 days) activates alkaline phosphatase (ALP), promotes the osteoblast differentiation and inhibits the osteoclast differentiation^[3].
Loganic acid (0-50 µM, 24 h) inhibits NF-κB nuclear translocation, activates Nrf2 translocation, and reduces the expressions of proinflammatory cytokine (IL-1β, IL-6, TNF-α) in LPS (HY-D1056)-stimulated RAW264.7 cell^[4].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Cell Viability Assay^[2]

Cell Line:

PBMC
Concentration:

100 μg/mL
Incubation Time:

24 h
Result:

Improved HgCl₂-inhibited cell viability of PBMC.

Immunofluorescence^[4]

Cell Line:

RAW 264.7
Concentration:

0-50 µM
Incubation Time:

24 h
Result:

Inhibited the nuclear translocation of NF-κB.
Activated the nuclear translocation and accumulation of Nrf2.

In Vivo

Loganic acid (20 mg/kg, po, daily for 60 days) exhibits anti-oxidation and anti-atherosclerosis activities in rabbit hypercholesterolemia models^[1].
Loganic acid (2-50 mg/kg, po, once daily for 12 weeks) prevents OVX-induced bone loss and increases bone mineral density in OVX-induced osteoporosis mouse model^[3].
Loganic acid (15-30 mg/kg, po, once daily for 14 days) ameliorates DSS (HY-116282C)-induced ulcerative colitis in mouse models^[4].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:

Rabbit hypercholesterolemia models^[1]
Dosage:

20 mg/kg
Administration:

po, daily for 60 days
Result:

Reduced the formation of atherosclerotic plaques in the thoracic aorta and abdominal aorta.
Reduced the level of MDA in the liver, increased the levels of GSH.
Improved the activity of glutathione peroxidase (Gpx).

Animal Model:

OVX-induced osteoporosis mouse model^[3]
Dosage:

2-50 mg/kg
Administration:

po, once daily for 12 weeks
Result:

Prevented bone density loss and improved bone structure in OVX mice.

Animal Model:

DSS (HY-116282C)-induced ulcerative colitis in mouse models^[4]
Dosage:

15-30 mg/kg
Administration:

po, once daily for 14 days
Result:

Reduced DSS-induced weight loss, blood in stool.
Prevented colon shortening and splenomegaly.

Chemical Information

CAS No. 22255-40-9
Appearance Solid
Molecular Weight 376.36
Formula C₁₆H₂₄O₁₀
Color White to yellow
SMILES

O[C@H]([C@@H](O)[C@@H]1O)[C@](O[C@@H]1CO)([H])O[C@H]2[C@@]([C@H]3C)([H])[C@@](C[C@@H]3O)([H])C(C(O)=O)=CO2
Structure Classification
- Terpenoids
- Iridoids
Initial Source
Shipping

Room temperature in continental US; may vary elsewhere.
Storage

4°C, protect from light

* In solvent : -80°C, 6 months; -20°C, 1 month (protect from light)

Solvent & Solubility

In Vitro:

DMSO : 50 mg/mL (132.85 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

View the Complete Stock Solution Preparation Table

Preparing Stock Solutions

View the Complete Stock Solution Preparation Table

Concentration Solvent Mass

1 mg

5 mg

10 mg

Concentration

Solvent

Mass

1 mM

2.6570 mL

13.2852 mL

26.5703 mL

5 mM

0.5314 mL

2.6570 mL

5.3141 mL

10 mM

0.2657 mL

1.3285 mL

2.6570 mL

Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.

Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (protect from light). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

Molarity Calculator

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass Mass

Concentration Concentration

Volume Volume

Molecular Weight Molecular Weight

Dilution Calculator

Concentration _(start) × Volume _(start) = Concentration _(final) × Volume _(final)

Concentration _(start) Concentration _(start)

Volume _(start) Volume _(start)

Concentration _(final) Concentration _(final)

Volume _(final) Volume _(final)

In Vivo:

Select the appropriate dissolution method based on your experimental animal and administration route.

Stock Solution Working Solution

For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline

Solubility: ≥ 2.5 mg/mL (6.64 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.

Protocol 2

Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)

Solubility: ≥ 2.5 mg/mL (6.64 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.

Protocol 3

Add each solvent one by one: 10% DMSO 90% Corn Oil

Solubility: ≥ 2.5 mg/mL (6.64 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown). If the continuous dosing period exceeds half a month, please choose this protocol carefully.

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL Corn oil, and mix evenly.

In Vivo Dissolution Calculator

Please enter the basic information of animal experiments:

Dosage Dosage
mg/kg
Animal Weight (Per Animal) Animal Weight (Per Animal)
g
Dosing Volume (Per Animal) Dosing Volume (Per Animal)
μL
Number of Animals Number of Animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Please enter your animal formula composition:

%
DMSO +

Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
%
+
+
%
Tween-80 + +
%
Saline +

The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).

Working solution concentration: 0.22 mg/mL

Purity & Documentation

Select Batch:

Purity: 99.98%

Assay: 99.98%

ee.: 99.98%

Data Sheet (285 KB)
SDS (393 KB)
- English - EN (393 KB)
- Français - FR (393 KB)
- Deutsch - DE (393 KB)
- Norwegian - NO (393 KB)
- Español - ES (393 KB)
- Swedish - SV (393 KB)
- Italian - IT (393 KB)
- Korean - KR (393 KB)
- Portuguese - PT (393 KB)
COA (2659 KB)
Elemental Analysis Report (2659 KB)
HNMR (2659 KB)
CNMR (2659 KB)
RP-HPLC (2659 KB)
NP-HPLC (2659 KB)
MS (2659 KB)
LCMS (2659 KB)
IR (2659 KB)
GC (2659 KB)
OR (2659 KB)
SDS-PAGE (2659 KB)
SEC-HPLC (2659 KB)
Other Report (2659 KB)
Handling Instructions (2659 KB)

References

[1]. Sozański T, et al. Loganic acid and anthocyanins from cornelian cherry (Cornus mas L.) fruits modulate diet-induced atherosclerosis and redox status in rabbits. Adv Clin Exp Med. 2018 Nov;27(11):1505-1513. [Content Brief]

[2]. Abirami A, et al. Antioxidant and cytoprotective properties of loganic acid isolated from seeds of Strychnos potatorum L. against heavy metal induced toxicity in PBMC model. Drug Chem Toxicol. 2019 Oct 23:1-11. [Content Brief]

[3]. Park E, et al., Osteoprotective Effects of Loganic Acid on Osteoblastic and Osteoclastic Cells and Osteoporosis-Induced Mice. Int J Mol Sci. 2020 Dec 28;22(1):233. [Content Brief]

[4]. Prakash AN, et al. Loganic acid protects against ulcerative colitis by inhibiting TLR4/NF-κB mediated inflammation and activating the SIRT1/Nrf2 anti-oxidant responses in-vitro and in-vivo. Int Immunopharmacol. 2023 Sep;122:110585. [Content Brief]

Help & FAQs

How should lyophilized recombinant proteins be reconstituted and stored?

1. Before opening the cap, centrifuge the vial at 13000 rpm for 20-30 seconds. This step will ensure that any lyophilized powder that may have adhered to the cap or walls is collected at the bottom of the vial, minimizing the risk of product loss.

Complete Stock Solution Preparation Table

Optional Solvent	Concentration Solvent Mass	1 mg	5 mg	10 mg	25 mg
DMSO	1 mM	2.6570 mL	13.2852 mL	26.5703 mL	66.4258 mL
	5 mM	0.5314 mL	2.6570 mL	5.3141 mL	13.2852 mL
	10 mM	0.2657 mL	1.3285 mL	2.6570 mL	6.6426 mL
	15 mM	0.1771 mL	0.8857 mL	1.7714 mL	4.4284 mL
	20 mM	0.1329 mL	0.6643 mL	1.3285 mL	3.3213 mL
	25 mM	0.1063 mL	0.5314 mL	1.0628 mL	2.6570 mL
	30 mM	0.0886 mL	0.4428 mL	0.8857 mL	2.2142 mL
	40 mM	0.0664 mL	0.3321 mL	0.6643 mL	1.6606 mL
	50 mM	0.0531 mL	0.2657 mL	0.5314 mL	1.3285 mL
	60 mM	0.0443 mL	0.2214 mL	0.4428 mL	1.1071 mL
	80 mM	0.0332 mL	0.1661 mL	0.3321 mL	0.8303 mL
	100 mM	0.0266 mL	0.1329 mL	0.2657 mL	0.6643 mL

Keywords

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent:

Product Name:
CAS No.:
Species:
Purity:
Quantity:

Loganic acid

Immunology/Inflammation Compound Library

Metabolism/Protease Compound Library

NF-κB Signaling Compound Library

Stem Cell Signaling Compound Library

Natural Product Library

Anti-Cancer Compound Library

Anti-Aging Compound Library

Antioxidant Compound Library

Differentiation Inducing Compound Library

Glycoside Compound Library

Lipid Compound Library

Oxygen Sensing Compound Library

Ferroptosis Compound Library

Medicine Food Homology Compound Library

Terpenoids Library

Pyroptosis Compound Library

Orally Active Compound Library

Traditional Chinese Medicine Active Compound Library

Anti-Breast Cancer Compound Library

Anti-Pancreatic Cancer Compound Library

Anti-Blood Cancer Compound Library

Anti-Cancer Metabolism Compound Library

Anti-Obesity Compound Library

Transcription Factor-Targeted Library

Anti-Liver Cancer Compound Library

Anti-Cancer Natural Product Library

Antidepressant Compound Library

Anti-inflammatory Traditional Chinese Medicine Active Compound Library

Plant-Sourced Natural Product Library

Anti-Prostate Cancer Compound Library

Anti-Pulmonary Fibrosis Compound Library

Cancer Stem Cells Compound Library

Heterocyclic Compound Library

Pain-Related Compound Library

Metabolic Enzyme Compound Library

Anti-Hematopathy Compound Library

Anti-Ovarian Cancer Compound Library

Multi-Target Compound Library

Radioprotector Library

Bioactive Compound Library Max

MCE Bioactive Compound Library

Natural Product Library Plus

Natural Product and Natural Product-Like Compound Library

Bioactive Compound Library

Fatty Acids Compound Library

Anti-Fibrosis Compound Library

Miao Ethnicity Medicine Compound Library

Tibetan Medicine Compound Library

Heat-Clearing and Detoxification Traditional Chinese Medicine Compound Library

Non-Alcoholic Fatty Liver Disease (NAFLD) Compound Library

Cell Proliferation Compound Library

High-Throughput Bioactive Compound Library

High-Throughput Natural Product Library

Ancient Chinese Classical Formulas Traditional Chinese Medicine Active Compound Library

Diarrhea-Related Traditional Chinese Medicine Active Compound Library

Mongolian Medicine Compound Library

Lactylation Compound Library

Mass Spectrometry Natural Product Library

All NF-κB Isoforms

Biological Activity

Chemical Information

Solvent & Solubility

Purity & Documentation

References

Help & FAQs

Complete Stock Solution Preparation Table

Loganic acid Related Classifications

HY-N0513 Related Classifications